Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · Pirtobrutinib monotherapy (continuous, BRUIN schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-PIRTOBRUTINIB |
| ID | IND-CLL-3L-PIRTOBRUTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CLL |
| Sources | SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Co-Lead sign-off. Aggressive-track 3L+ option for r/r CLL post-cBTKi resistance. Particularly indicated for BTK-C481 and TP53-mutated subsets. CAR-T (lisocabtagene maraleucel, TRANSCEND CLL 004) is the alternative cellular therapy — separate future Indication. UA access barrier is dominant (not registered, no domestic supply).
Used By
Algorithms
ALGO-CLL-2L- ALGO-CLL-2L
Indication
IND-CLL-3L-LISOCEL- IND-CLL-3L-LISOCEL